Page last updated: 2024-10-27

gabapentin and Diabetes Mellitus, Adult-Onset

gabapentin has been researched along with Diabetes Mellitus, Adult-Onset in 18 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy."9.14Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010)
"Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg."7.72[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003)
"Compared with gabapentin, duloxetine has no obvious advantage in the treatment of diabetic peripheral neuralgia, but it has less side effects and significantly higher safety."5.22Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis. ( Cui, J; Jiang, L; Xiong, Y, 2022)
"This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy."5.14Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010)
"Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg."3.72[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003)
"Thirty patients with type 2 diabetes with peripheral neuropathy as assessed by a visual analog scale (VAS) and divided into two groups of 15 patients, treated for up to three months."3.30Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial. ( Ahmadi, SA; Bagheri, S; Dolatkhah, H; Hassanzadeh, S; Majid Ahmadi, S; Moradishibany, I; Reisi, S, 2023)
"Mycophenolic acid was detected in all cats."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Given the rising prevalence of painful diabetic neuropathy, it is increasingly important that we understand the best ways to diagnose and treat this condition."2.50Painful diabetic neuropathy. ( Callaghan, BC; Goutman, SA; Peltier, A, 2014)
"Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work."2.44Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007)
"Persistent hiccups have been reported to occur occasionally during rehabilitation hospitalizations."2.44Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature. ( Browne, BA; Schuchmann, JA, 2007)
"Gabapentin treatment was initiated after baseline evaluation, and the RDD and visual analog scale (VAS) score were both evaluated regularly during the 2-week study period."1.72Rate-Dependent Depression: A Predictor of the Therapeutic Efficacy in Treating Painful Diabetic Peripheral Neuropathy. ( Calcutt, NA; Guan, Y; Lin, Z; Wang, Z; Xie, C; Zhou, X; Zhu, D; Zhu, Y, 2022)
"Gabapentin was restarted at the original dosage and the symptoms resolved within 8 hours."1.37Akathisia induced by gabapentin withdrawal. ( Hendriks, E; Hsiung, L; See, S, 2011)
"The basis of the treatment of painful diabetic neuropathy is the use of drugs that block the transmission of pain (antineuritics) and a good metabolic control of underlying disease."1.33[Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy]. ( Bastías A, MJ; Olmos C, P; Toro C, L, 2006)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (38.89)29.6817
2010's7 (38.89)24.3611
2020's4 (22.22)2.80

Authors

AuthorsStudies
Zhou, X1
Zhu, Y1
Wang, Z2
Lin, Z1
Zhu, D2
Xie, C1
Calcutt, NA1
Guan, Y1
Jiang, L1
Xiong, Y1
Cui, J1
Hassanzadeh, S1
Bagheri, S1
Majid Ahmadi, S1
Ahmadi, SA1
Moradishibany, I1
Dolatkhah, H1
Reisi, S1
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B1
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y4
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J5
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Y4
Hu, X1
Li, Z2
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y3
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Peng, J1
Jia, Z1
Li, F1
Chen, X2
Mo, J1
Zhang, S2
Li, X1
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Costa, ACC1
de Lima Benzi, JR1
Yamamoto, PA1
de Freitas, MCF1
de Paula, FJA1
Zanelli, CF1
Lauretti, GR1
de Moraes, NV1
Hsu, CH1
Yu, SM1
Lau, SC1
Chen, YL1
Pei, D1
Liu, IC1
Kalso, E1
Aldington, DJ1
Moore, RA1
Peltier, A1
Goutman, SA1
Callaghan, BC1
Forde, G1
Stanos, S1
Sandercock, D1
Cramer, M1
Wu, J1
Chiang, YK1
Biton, V1
Heritier, M1
Ko, SH1
Kwon, HS1
Yu, JM1
Baik, SH1
Park, IB1
Lee, JH1
Ko, KS1
Noh, JH1
Kim, DS1
Kim, CH1
Mok, JO1
Park, TS1
Son, HS1
Cha, BY1
See, S1
Hendriks, E1
Hsiung, L1
Hosseini-Zare, MS1
Dashti-Khavidaki, S1
Mahdavi-Mazdeh, M1
Ahmadi, F1
Akrami, S1
Paradowski, B1
Bilinska, M1
Bastías A, MJ1
Toro C, L1
Olmos C, P1
Schuchmann, JA1
Browne, BA1
Derk, CT1
Cynwyd, B1
Azulay, JP1
Pouget, J1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of BIODEX Balance System Training on Balance in Type II-diabetic Neuropathy.[NCT04943614]88 participants (Actual)Interventional2020-12-01Completed
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297]301 participants (Anticipated)Interventional2022-11-01Recruiting
A Double-Blind, Placebo Controlled Trial of Intravenous Immunoglobulin Therapy in Patient With Small Fiber Neuropathy Associated With Autoantibodies to TS-HDS and FGFR3[NCT03401073]Phase 220 participants (Actual)Interventional2018-09-01Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy[NCT00712439]Phase 2147 participants (Actual)Interventional2006-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

2) The Difference in Change Between Quantified Utah Early Neuropathy Examination Scores, Between Treatment and Placebo Groups Between Visits 1 and 8.

"The Utah Early Neuropathy Scale (UENS) was developed specifically to detect and quantify early small-fiber sensory neuropathy and to recognize modest changes in sensory severity and distribution.~The UENS scale ranges from 0 (no neuropathy) to 42 (severe small fiber neuropathy). The outcome measure is the UENS score from Visit 8 minus the UENS score at visit 1. The difference in the two scores indicates the change in neuropathy severity. A positive value indicates that neuropathy has worsened over the course of the study, a negative value indicates that neuropathy has improved over the course of the study." (NCT03401073)
Timeframe: Visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).

Interventionunits on a scale (Mean)
0.9% Sodium Chloride-3.0
Intravenous Immunoglobulin-1.8

The Change in Nerve Fiber Density Between Visits 1 and 8.

"Difference in intra-epidermal nerve fiber density between visits 1 and 8 will be measured.~Intra-epidermal nerve fiber density is a quantitative measure of the number of nerve fibers per millimeter. The outcome is the number of nerve fibers measured at visit 8 minus the number of nerve fibers measured at visit 1. A positive value indicates that nerve fiber density has increased (a better outcome), a negative value indicates that the nerve fiber density has decreased (a worse outcome)." (NCT03401073)
Timeframe: Visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).

Interventionfibers/mm (Mean)
0.9% Sodium Chloride0.5
Intravenous Immunoglobulin0.6

The Change in Neuropathic Pain Severity Between Visits 1 and 8.

"The visual analog scale (VAS) of pain allows for quantification of neuropathic pain.~The VAS pain scale depicts a line ranging from 0 (no pain) to 10 (worst possible pain). The scale is ordinal ranging from 0-10.~The difference in pain between visit 1 and visit 8 (pain measured at visit 8 subtracted from the score at visit 1) is the range. Positive values indicate an increase in pain (worse outcome), negative values indicate an improvement in pain (better outcome)." (NCT03401073)
Timeframe: Visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).

Interventionunits on a scale (Mean)
0.9% Sodium Chloride-1.7
Intravenous Immunoglobulin-1.9

Reviews

5 reviews available for gabapentin and Diabetes Mellitus, Adult-Onset

ArticleYear
Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis.
    Contrast media & molecular imaging, 2022, Volume: 2022

    Topics: Analgesics; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Duloxetine Hydrochlor

2022
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Painful diabetic neuropathy.
    BMJ (Clinical research ed.), 2014, May-06, Volume: 348

    Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type

2014
Practical management strategies for the chronic pain patient.
    The Journal of family practice, 2007, Volume: 56, Issue:8 Suppl Ho

    Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro

2007
Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature.
    American journal of physical medicine & rehabilitation, 2007, Volume: 86, Issue:12

    Topics: Aged; Amines; Anti-Anxiety Agents; Anticonvulsants; Cerebral Infarction; Chlorpromazine; Chronic Dis

2007

Trials

3 trials available for gabapentin and Diabetes Mellitus, Adult-Onset

ArticleYear
Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial.
    BMC endocrine disorders, 2023, Oct-16, Volume: 23, Issue:1

    Topics: Amines; Analgesics; Clonidine; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Neur

2023
Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial.
    Diabetes care, 2009, Volume: 32, Issue:2

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Diabetes Mellitus, Typ

2009
Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy.
    Diabetic medicine : a journal of the British Diabetic Association, 2010, Volume: 27, Issue:9

    Topics: Acetaminophen; Adult; Aged; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Diabetes Mellit

2010

Other Studies

10 other studies available for gabapentin and Diabetes Mellitus, Adult-Onset

ArticleYear
Rate-Dependent Depression: A Predictor of the Therapeutic Efficacy in Treating Painful Diabetic Peripheral Neuropathy.
    Diabetes, 2022, 06-01, Volume: 71, Issue:6

    Topics: Depression; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Gabapentin; Humans; Pain

2022
Population pharmacokinetics of gabapentin in patients with neuropathic pain: Lack of effect of diabetes or glycaemic control.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:4

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Gabapentin; Glycemic Con

2021
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
    Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2017, Volume: 17, Issue:6

    Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B

2017
Drugs for neuropathic pain.
    BMJ (Clinical research ed.), 2013, Dec-19, Volume: 347

    Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Neuropathies; D

2013
Akathisia induced by gabapentin withdrawal.
    The Annals of pharmacotherapy, 2011, Volume: 45, Issue:6

    Topics: Aged; Akathisia, Drug-Induced; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Mellitus, T

2011
Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure.
    Clinical neurology and neurosurgery, 2012, Volume: 114, Issue:6

    Topics: Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Ne

2012
[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2003, Volume: 15, Issue:85

    Topics: Acetates; Aged; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ty

2003
[Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy].
    Revista medica de Chile, 2006, Volume: 134, Issue:12

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Analgesics; Clomipramine; Cyclohexanecarboxylic A

2006
Malignant appearing cachexia in an older patient with Bruns-Garland syndrome.
    Journal of the American Geriatrics Society, 2000, Volume: 48, Issue:12

    Topics: Acetates; Aged; Amines; Analgesics; Cachexia; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2

2000
[Diabetic neuropathies].
    La Revue du praticien, 2001, Oct-15, Volume: 51, Issue:16

    Topics: Acetates; Amines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbamazepine; Controlled Clinic

2001